AbbVie (ABBV) Market Capitalization, Earnings, Price, Holders
Symbol: ABBV Rank: #31 Price: $147.35(-1.27303%)

Market Cap: $264B($-3.3B) Industry: Drug Manufacturers General Sector: Healthcare Country: United States Insiders: 0.125% Institutions: 71.527%
AbbVie Inc. Technicals

52 Week High: $169.46

52 Week Low: $131.49

50 Day MA: $153.75

200 Day MA: $149.03

52 Week Trading Range


Low: $131.49

High: $169.46

Daily Trading Range


Low: $146.35

High: $149.03

Market capitalization history for AbbVie (ABBV) in USD

As of November 2023, AbbVie (ABBV) has a market cap of $264 billion. Our data points out that ABBV is ranked #31 in the world. A company's market capitalization is the present value of all of its outstanding shares, and it is commonly used to give a sense of how much the stock of a company would be worth at today's exchange rates. ABBV's market cap is -1.27303% down from the last trading day.

ABBV Statistics

Market Cap
Revenue TTM
Gross Profit TTM
Operating Margin TTM
Shares Outstanding
Shares Float
Trading Volume
P/E Ratio
PEG Ratio
Revenue Per Share
Dividend Per Share
Dividend Yield
Quote Type
Leaf logo
CDP Climate Change Score (ABBV)

Latest News

AbbVie (ABBV) Shares Stats
AbbVie (ABBV) Valuation
Trailing P/E $23.481
Forward P/E $14.3885
Price Sales TTM $4.9887
Price Book MRQ $18.2288
Enterprise Value $349,278,696,548
Enterprise Value Revenue $6.0409
Enterprise Value Ebitda $13.7968
AbbVie Inc. Details

Address: 1 North Waukegan Road

City: North Chicago

Zip: 60064-6400

Phone: 847 932 7900


IPO Date: 2013-01-02

CEO: Richard A. Gonzalez

Employees: 50,000

What is ABBV about?

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.